Literature DB >> 27411724

Con: Higher serum bicarbonate in dialysis patients is protective.

Philippe Chauveau1, Claire Rigothier2, Christian Combe2.   

Abstract

Metabolic acidosis is often observed in advanced chronic kidney disease, with deleterious consequences on the nutritional status, bone and mineral status, inflammation and mortality. Through clearance of the daily acid load and a net gain in alkaline buffers, dialysis therapy is aimed at correcting metabolic acidosis. A normal bicarbonate serum concentration is the recommended target in dialysis patients. However, several studies have shown that a mild degree of metabolic acidosis in patients treated with dialysis is associated with better nutritional status, higher protein intake and improved survival. Conversely, a high bicarbonate serum concentration is associated with poor nutritional status and lower survival. It is likely that mild acidosis results from a dietary acid load linked to animal protein intake. In contrast, a high bicarbonate concentration in patients treated with dialysis could result mainly from an insufficient dietary acid load, i.e. low protein intake. Therefore, a high pre-dialysis serum bicarbonate concentration should prompt nephrologists to carry out nutritional investigations to detect insufficient dietary protein intake. In any case, a high bicarbonate concentration should be neither a goal of dialysis therapy nor an index of adequate dialysis, whereas mild acidosis could be considered as an indicator of appropriate protein intake.
© The Author 2016. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  chronic kidney disease; dialysis; haemodialysis; metabolic acidosis; peritoneal dialysis

Mesh:

Substances:

Year:  2016        PMID: 27411724     DOI: 10.1093/ndt/gfw255

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  1 in total

1.  The dynamics of the metabolism of acetate and bicarbonate associated with use of hemodialysates in the ABChD trial: a phase IV, prospective, single center, single blind, randomized, cross-over, two week investigation.

Authors:  William B Smith; Sandy Gibson; George E Newman; Kendra S Hendon; Margarita Askelson; James Zhao; Jamil Hantash; Brigid Flanagan; John W Larkin; Len A Usvyat; Ravi I Thadhani; Franklin W Maddux
Journal:  BMC Nephrol       Date:  2017-08-29       Impact factor: 2.388

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.